Ranitidine duty suspension
Executive Summary
Subject of Sept. 24 hearing by Ways & Means/Trade Subcommittee will be legislation (HR 3130) temporarily suspending duty on ranitidine hydrochloride, the active ingredient in Glaxo's Zantac. Witnesses will include Glaxo and SmithKline Beecham. Glaxo maintains that the duty suspension would result in loss of Treasury revenues of $7-$9 mil. per year, based on CBO figures.